Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      the Departments of Pediatric and Adolescent Oncology in the United Kingdom
      INSERM Unite 1015 in the United Kingdom
      the Unit of Biostatistics and Epidemiology and INSERM Unite 1018 in the United Kingdom
      Gustave Roussy, Universite Paris-Saclay, Villejuif, France
      the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy
      the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge in the United Kingdom
      the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles
      Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham in the United Kingdom
      the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain
      the Division of Haematology-Oncology, Hospital for Sick Children, Toronto
      the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
      the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC
      Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands
      the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary
      the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland
      the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
      the Department of Pathology, University of Utah, Salt Lake City
      the Department of Histopathology, Royal Marsden NHS Foundation Trust, London in the United Kingdom
      Children's Hospital of Philadelphia, Philadelphia
      Clinical Research in the United Kingdom
      the National Cancer Institute, Center for Global Health, Rockville, MD
    • Journal Subset:
      Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA
    • ISSN:
      0028-4793
    • MEDLINE Info:
      NLM UID: 0255562
    • Publication Date:
      20200611
    • Publication Date:
      20200617
    • DOI:
      http://dx.doi.org/10.1056/NEJMoal915315
    • Accession Number:
      143648968
  • Citations
    • ABNT:
      MINARD-COLIN, V. et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. New England Journal of Medicine, [s. l.], v. 382, n. 23, p. 2207–2219, 2020. DOI 10.1056/NEJMoal915315. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143648968. Acesso em: 4 ago. 2020.
    • AMA:
      Minard-Colin V, Auperir A, Pillon M, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. New England Journal of Medicine. 2020;382(23):2207-2219. doi:10.1056/NEJMoal915315.
    • AMA11:
      Minard-Colin V, Auperir A, Pillon M, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. New England Journal of Medicine. 2020;382(23):2207-2219. doi:10.1056/NEJMoal915315
    • APA:
      Minard-Colin, V., Auperir, A., Pillon, M., Burke, G. A. A., Barkauskas, D. A., Wheatley, K., Delgado, R. F., Alexander, S., Uyttebroeck, A., Bollard, C. M., Zsiros, J., Csoka, M., Kazanowska, B., Chiang, A. K., Miles, R. R., Wotherspoon, A., Adamson, P. C., Vassal, G., Patte, C., & Gross, T. G. (2020). Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. New England Journal of Medicine, 382(23), 2207–2219. https://doi.org/10.1056/NEJMoal915315
    • Chicago/Turabian: Author-Date:
      Minard-Colin, V., A. Auperir, M. Pillon, G. A. A. Burke, D. A. Barkauskas, K. Wheatley, R. F. Delgado, et al. 2020. “Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children.” New England Journal of Medicine 382 (23): 2207–19. doi:10.1056/NEJMoal915315.
    • Harvard:
      Minard-Colin, V. et al. (2020) ‘Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children’, New England Journal of Medicine, 382(23), pp. 2207–2219. doi: 10.1056/NEJMoal915315.
    • Harvard: Australian:
      Minard-Colin, V, Auperir, A, Pillon, M, Burke, GAA, Barkauskas, DA, Wheatley, K, Delgado, RF, Alexander, S, Uyttebroeck, A, Bollard, CM, Zsiros, J, Csoka, M, Kazanowska, B, Chiang, AK, Miles, RR, Wotherspoon, A, Adamson, PC, Vassal, G, Patte, C & Gross, TG 2020, ‘Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children’, New England Journal of Medicine, vol. 382, no. 23, pp. 2207–2219, viewed 4 August 2020, .
    • MLA:
      Minard-Colin, V., et al. “Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children.” New England Journal of Medicine, vol. 382, no. 23, June 2020, pp. 2207–2219. EBSCOhost, doi:10.1056/NEJMoal915315.
    • Chicago/Turabian: Humanities:
      Minard-Colin, V., A. Auperir, M. Pillon, G. A. A. Burke, D. A. Barkauskas, K. Wheatley, R. F. Delgado, et al. “Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children.” New England Journal of Medicine 382, no. 23 (June 4, 2020): 2207–19. doi:10.1056/NEJMoal915315.
    • Vancouver/ICMJE:
      Minard-Colin V, Auperir A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. New England Journal of Medicine [Internet]. 2020 Jun 4 [cited 2020 Aug 4];382(23):2207–19. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143648968